Labeling Expanded for Valsartan

Novartis Pharmaceuticals has announced that the FDA has approved valsartan (Diovan tablet), an angiotensin receptor blocker, to reduce cardiovascular deaths in high-risk patients (those with left ventricular failure or dysfunction) after a heart attack.

The FDA also expanded the drug’s labeling for heart failure. Valsartan drug, indicated for the first-line treatment of hypertension, can now be prescribed for a broader range of patients and is no longer limited to patients with an intolerance of angiotensin-converting enzyme (ACE) inhibitors.